研究者詳細 - 宮原　信明

論文 - 宮原　信明

分割表示 179 件中 21 - 40 件目／全件表示 >>

Mycobacterium shinjukuense infection successfully treated with clarithromycin, rifampicin, and ethambutol. 査読国際誌

Kayo Nakamura, Etsuko Murakami, Daizo Kishino, Shuko Mashimo, Yusuke Kurioka, Yusaku Shibata, Arihiko Taniguchi, Hisao Higo, Yasushi Hiramatsu, Yoshinobu Maeda, Nobuaki Miyahara

Respiratory medicine case reports 45 101894 - 101894 2023年

担当区分：最終著者,　責任著者記述言語：英語

We present the case of a 59-year-old woman diagnosed with Mycobacterium shinjukuense infection using mass spectrometry of bronchioalveolar lavage fluid. We initiated treatment with clarithromycin, rifampicin, and ethambutol based on the results of drug susceptibility testing, which improved lung opacities. Most previous cases were treated with the standard regimen for Mycobacterium tuberculosis. However, our regimen may provide a therapeutic option for this rare nontuberculous Mycobacterium infection.

DOI： 10.1016/j.rmcr.2023.101894

PubMed

researchmap

Nationwide survey of refractory asthma with bronchiectasis by inflammatory subtypes 査読国際誌

Respiratory Research 23 ( 1 ) 365 - 365 2022年12月

Intravenous immunoglobulin for acute exacerbation of fibrotic idiopathic interstitial pneumonias: IV immunoglobulin for acute exacerbation of fibrotic IIPs 査読国際誌

Hisao Higo, Hirohisa Ichikawa, Naoki Nakamura, Masanori Fujii, Katsuhiro Matsuoka, Shoko Seki, Takamasa Wada, Noriyuki Suzaki, Takuya Nagata, Yukako Arakawa, Yoshihiro Mori, Masaomi Marukawa, Katsuyuki Kiura, Yoshinobu Maeda, Nobuaki Miyahara

Sarcoidosis, Vasculitis and Diffuse Lung Diseases 2022年11月

Neuropeptide Y Antagonizes Development of Pulmonary Fibrosis Through IL-1β Inhibition. 査読国際誌

Junko Itano, Akihiko Taniguchi, Satoru Senoo, Noboru Asada, Yuka Gion, Yuria Egusa, Lili Guo, Naohiro Oda, Kota Araki, Yasuharu Sato, Shinichi Toyooka, Katsuyuki Kiura, Yoshinobu Maeda, Nobuaki Miyahara

American journal of respiratory cell and molecular biology 67 ( 6 ) 654 - 665 2022年9月

Use of a highly sensitive lung cancer compact panel to detect KRAS G12D in the wash fluid from a lung tumor: A case report. 査読国際誌

Daisuke Minami, Nagio Takigawa, Yasuhiro Nakajima, Nobuaki Miyahara, Yasuyuki Mizumori, Mitsuhiro Ueda, Seiji Nakamura, Fumihiko Suzuki, Yoshiharu Sato, Kei Morikawa, Arihiko Kanehiro

Thoracic cancer 2022年5月

A case of Fulminant Respiratory Failure Caused by Anti-asparaginyl tRNA Synthetase (Anti-KS) Antibody Syndrome-related Interstitial Lung Disease. 査読国際誌

Naohiro Oda, Akihiko Taniguchi, Toshiyuki Aokage, Satoru Senoo, Kenta Nagashima, Reo Mitani, Ichiro Takata, Nobuaki Miyahara

2022年4月

Identification of targetable kinases in idiopathic pulmonary fibrosis. 査読国際誌

Hisao Higo, Kadoaki Ohashi, Shuta Tomida, Sachi Okawa, Hiromasa Yamamoto, Seiichiro Sugimoto, Satoru Senoo, Go Makimoto, Kiichiro Ninomiya, Takamasa Nakasuka, Kazuya Nishii, Akihiko Taniguchi, Toshio Kubo, Eiki Ichihara, Katsuyuki Hotta, Nobuaki Miyahara, Yoshinobu Maeda, Shinichi Toyooka, Katsuyuki Kiura

23 ( 1 ) 20 - 20 2022年2月

Protective effects of neuropeptide Y against elastase-induced pulmonary emphysema. 査読国際誌

Akihiko Taniguchi, Naohiro Oda, Daisuke Morichika, Satoru Senoo, Junko Itano, Utako Fujii, Lili Guo, Ryota Sunami, Katsuyuki Kiura, Yoshinobu Maeda, Nobuaki Miyahara

American journal of physiology. Lung cellular and molecular physiology 322 ( 4 ) L539-L549 2022年2月

担当区分：最終著者,　責任著者記述言語：英語掲載種別：研究論文（学術雑誌）

Neuropeptide Y (NPY) is a neuropeptide widely expressed in not only the central nervous system but also immune cells and the respiratory epithelium. Patients with chronic obstructive pulmonary disease (COPD) reportedly exhibit decreased NPY expression in the airway epithelium, but the involvement of NPY in the pathophysiology of COPD has not been defined. We investigated the role of NPY in elastase-induced emphysema. NPY-deficient (NPY-/-) mice and wild-type (NPY+/+) mice received intratracheal instillation of porcine pancreas elastase (PPE). The numbers of inflammatory cells and the levels of cytokines and chemokines in the bronchoalveolar lavage (BAL) fluid and lung homogenates were determined along with quantitative morphometry of lung sections. Intratracheal instillation of PPE induced emphysematous changes and increased NPY levels in the lungs. Compared with NPY+/+ mice, NPY-/- mice had significantly enhanced PPE-induced emphysematous changes and alveolar enlargement. Neutrophilia seen in BAL flu12id of NPY+/+ mice on day 4 after PPE instillation was also enhanced in NPY-/- mice, and the enhancement was associated with increased levels of neutrophil-related and macrophage-related chemokines and IL-17A as well as increased numbers of type 3 innate lymphoid cells in the airways. Treatment with NPY significantly reduced PPE-induced emphysematous changes. Conversely, treatment with a NPY receptor antagonist exacerbated PPE-induced emphysematous changes. These observations indicate that NPY has protective effects against elastase-induced emphysema, and suggest that targeting NPY in emphysema has potential as a therapeutic strategy for delaying disease progression.

DOI： 10.1152/ajplung.00353.2020

PubMed

researchmap

新規生物学的製剤抗IL-33抗体

妹尾賢, 宮原信明

呼吸器内科 41 ( 1 ) 67 - 72 2022年1月

Nonepisodic angioedema with eosinophilia during sublingual immunotherapy with house dust mite extract. 査読国際誌

Naohiro Oda, Takahisa Koyama, Yuki Nakagawa, Nobuaki Miyahara

Allergology international : official journal of the Japanese Society of Allergology 71 ( 2 ) 254 - 255 2021年12月

The effects of inhaling hydrogen gas on macrophage polarization, fibrosis, and lung function in mice with bleomycin-induced lung injury. 査読国際誌

Toshiyuki Aokage, Mizuki Seya, Takahiro Hirayama, Tsuyoshi Nojima, Masumi Iketani, Michiko Ishikawa, Yasuhiro Terasaki, Akihiko Taniguchi, Nobuaki Miyahara, Atsunori Nakao, Ikuroh Ohsawa, Hiromichi Naito

BMC pulmonary medicine 21 ( 1 ) 339 - 339 2021年10月

記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: Acute respiratory distress syndrome, which is caused by acute lung injury, is a destructive respiratory disorder caused by a systemic inflammatory response. Persistent inflammation results in irreversible alveolar fibrosis. Because hydrogen gas possesses anti-inflammatory properties, we hypothesized that daily repeated inhalation of hydrogen gas could suppress persistent lung inflammation by inducing functional changes in macrophages, and consequently inhibit lung fibrosis during late-phase lung injury. METHODS: To test this hypothesis, lung injury was induced in mice by intratracheal administration of bleomycin (1.0 mg/kg). Mice were exposed to control gas (air) or hydrogen (3.2% in air) for 6 h every day for 7 or 21 days. Respiratory physiology, tissue pathology, markers of inflammation, and macrophage phenotypes were examined. RESULTS: Mice with bleomycin-induced lung injury that received daily hydrogen therapy for 21 days (BH group) exhibited higher static compliance (0.056 mL/cmH2O, 95% CI 0.047-0.064) than mice with bleomycin-induced lung injury exposed only to air (BA group; 0.042 mL/cmH2O, 95% CI 0.031-0.053, p = 0.02) and lower static elastance (BH 18.8 cmH2O/mL, [95% CI 15.4-22.2] vs. BA 26.7 cmH2O/mL [95% CI 19.6-33.8], p = 0.02). When the mRNA levels of pro-inflammatory cytokines were examined 7 days after bleomycin administration, interleukin (IL)-6, IL-4 and IL-13 were significantly lower in the BH group than in the BA group. There were significantly fewer M2-biased macrophages in the alveolar interstitium of the BH group than in the BA group (3.1% [95% CI 1.6-4.5%] vs. 1.1% [95% CI 0.3-1.8%], p = 0.008). CONCLUSIONS: The results suggest that hydrogen inhalation inhibits the deterioration of respiratory physiological function and alveolar fibrosis in this model of lung injury.

DOI： 10.1186/s12890-021-01712-2

PubMed

researchmap

Reactive Oxygen Species and Antioxidative Defense in Chronic Obstructive Pulmonary Disease. 招待査読国際誌

Akihiko Taniguchi, Mitsuru Tsuge, Nobuaki Miyahara, Hirokazu Tsukahara

Antioxidants (Basel, Switzerland) 10 ( 10 ) 2021年9月

記述言語：英語掲載種別：研究論文（学術雑誌）

The respiratory system is continuously exposed to endogenous and exogenous oxidants. Chronic obstructive pulmonary disease (COPD) is characterized by chronic inflammation of the airways, leading to the destruction of lung parenchyma (emphysema) and declining pulmonary function. It is increasingly obvious that reactive oxygen species (ROS) and reactive nitrogen species (RNS) contribute to the progression and amplification of the inflammatory responses related to this disease. First, we described the association between cigarette smoking, the most representative exogenous oxidant, and COPD and then presented the multiple pathophysiological aspects of ROS and antioxidative defense systems in the development and progression of COPD. Second, the relationship between nitric oxide system (endothelial) dysfunction and oxidative stress has been discussed. Third, we have provided data on the use of these biomarkers in the pathogenetic mechanisms involved in COPD and its progression and presented an overview of oxidative stress biomarkers having clinical applications in respiratory medicine, including those in exhaled breath, as per recent observations. Finally, we explained the findings of recent clinical and experimental studies evaluating the efficacy of antioxidative interventions for COPD. Future breakthroughs in antioxidative therapy may provide a promising therapeutic strategy for the prevention and treatment of COPD.

DOI： 10.3390/antiox10101537

PubMed

researchmap

Essential role of IL-23 in the development of acute exacerbation of pulmonary fibrosis. 査読国際誌

Satoru Senoo, Akihiko Taniguchi, Junko Itano, Naohiro Oda, Daisuke Morichika, Utako Fujii, Lili Guo, Ryota Sunami, Arihiko Kanehiro, Fumiaki Tokioka, Akihiko Yoshimura, Katsuyuki Kiura, Yoshinobu Maeda, Nobuaki Miyahara

American journal of physiology. Lung cellular and molecular physiology 321 ( 5 ) L925-L940 2021年9月

担当区分：最終著者,　責任著者記述言語：英語掲載種別：学位論文（博士）

Acute exacerbation of idiopathic pulmonary fibrosis has a poor prognosis associated with neutrophilic inflammation. Interleukin-23 is a proinflammatory cytokine involved in neutrophilic inflammation. However, little is known about its role in acute exacerbation of pulmonary fibrosis. This study was performed to determine the role of interleukin-23 in acute exacerbation of pulmonary fibrosis. For assessment of acute exacerbation of pulmonary fibrosis, mice were intratracheally administered bleomycin followed by lipopolysaccharide. Inflammatory cells, cytokine levels, and morphological morphometry of the lungs were analyzed. Cytokine levels were measured in the bronchoalveolar lavage fluid of idiopathic pulmonary fibrosis patients with or without acute exacerbation. Interleukin-23, -17A, and -22 levels were increased in the airway of mice with acute exacerbation of pulmonary fibrosis. Interleukin-23p19-deficient mice with acute exacerbation of pulmonary fibrosis had markedly reduced airway inflammation and fibrosis associated with decreased levels of interleukin-17A and -22 compared with wild-type mice. Treatment with an anti-interleukin-23 antibody attenuated airway inflammation and fibrosis and reduced interleukin-17A and -22 levels in mice with acute exacerbation of pulmonary fibrosis. T helper 17 cells were the predominant source of interleukin-17A in mice with acute exacerbation of pulmonary fibrosis. Interleukin-23 levels in bronchoalveolar lavage fluid tended to be higher in idiopathic pulmonary fibrosis patients with than without acute exacerbation. The data presented here suggest that interleukin-23 is essential for the development of acute exacerbation of pulmonary fibrosis, and that blockade of interleukin-23 may be a new therapeutic strategy for acute exacerbation of pulmonary fibrosis.

DOI： 10.1152/ajplung.00582.2020

PubMed

researchmap

Marginal Zone Lymphoma and Lung Adenocarcinoma with an EGFR Exon 19 E746-S752del Mutation in a Patient with IgG4-related Disease. 査読国際誌

Sachi Okawa, Kammei Rai, Nobuharu Fujii, Yuka Gion, Kiichiro Ninomiya, Yuka Kato, Akihiko Taniguchi, Toshio Kubo, Eiki Ichihara, Kadoaki Ohashi, Nobuaki Miyahara, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

Internal medicine (Tokyo, Japan) 60 ( 17 ) 2831 - 2837 2021年9月

記述言語：英語掲載種別：研究論文（学術雑誌）

A 68-year-old man presented with a solid mass at the left renal pelvis and ureter with multiple systemic lymphadenopathies and a mass with a cavity in the right lower lobe of the lung. While a transbronchial lung biopsy revealed no malignancy, a biopsy of the renal pelvis showed marginal zone lymphoma with polyclonal IgG4-positive cells. The serum IgG4 level and presence of a bilateral orbital mass suggested Mikulicz disease. The lesions shrank following the administration of steroids. A rebiopsy confirmed lung adenocarcinoma, and its background showed IgG4-positive cells a year later. IgG4-related diseases require careful follow-up because they can be complicated by malignancy.

DOI： 10.2169/internalmedicine.6470-20

PubMed

researchmap

The prevalence of comorbid respiratory disease among COVID-19 patients, and mortality during the first wave in Japan: A nationwide survey by the Japanese Respiratory Society. 国際誌

Hiroyuki Nagase, Yoshihiro Nishimura, Hisako Matsumoto, Naoya Sugimoto, Takashi Iwanaga, Akiko Sano, Satoshi Konno, Nobuyuki Hizawa, Koichiro Asano, Takahiko Horiguchi, Akihito Yokoyama

Respiratory investigation 59 ( 5 ) 679 - 682 2021年9月

記述言語：英語掲載種別：研究論文（学術雑誌）

There is a concern that persons with underlying respiratory disease may have increased susceptibility to COVID-19 and/or increased severity/mortality if infected. However, information regarding such patients during the first wave of the epidemic is lacking in Japan. We surveyed chest physicians nationwide, and collected anonymous data concerning 1444 patients. Among COVID-19 patients, the prevalence of asthma, chronic obstructive pulmonary disease (COPD), and interstitial lung diseases (ILD) was 3.4%, 4.8%, and 1.5%, respectively. Among COVID-19 patients with these 3 comorbidities, exacerbation of the comorbidity occurred in 12.2%, 18.8%, and 36.4%, respectively, and mortality (6.2% overall) was 4.1%, 13.0%, and 31.8%, respectively. The prevalence of asthma among COVID-19 patients was not higher than that for the general population, and mortality in COVID-19 patients with asthma was not higher than mortality in COVID-19 patients without underlying respiratory disease. COVID-19 patients having COPD or ILD had relatively high mortality, especially for ILD.

DOI： 10.1016/j.resinv.2021.06.008

PubMed

researchmap

Pulmonary Aspergilloma and Allergic Bronchopulmonary Aspergillosis Following the 2018 Heavy Rain Event in Western Japan: A Case Report. 査読国際誌

Eri Ando, Takamasa Nakasuka, Toshio Kubo, Akihiko Taniguchi, Kiichiro Ninomiya, Yuka Kato, Eiki Ichihara, Kadoaki Ohashi, Kammei Rai, Katsuyuki Hotta, Masaomi Yamane, Nobuaki Miyahara, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura

Internal medicine (Tokyo, Japan) 61 ( 3 ) 379 - 383 2021年8月

記述言語：英語掲載種別：研究論文（学術雑誌）

A 16-year-old boy with asthma participated in recovery volunteer work following the 2018 heavy rains in Japan. One month later, he experienced chest pain and dyspnea. Chest computed tomography revealed a cavity with a fungal ball, and Aspergillus fumigatus was detected in his bronchoalveolar lavage fluid. He was treated with voriconazole, but new consolidations appeared rapidly. He also experienced allergic bronchopulmonary aspergillosis. After prednisolone prescription, the consolidations improved; however, his asthma worsened. He underwent partial lung resection to avoid allergens, and his symptoms improved. We must recognize cases of infection after a disaster, especially in patients with chronic respiratory diseases.

DOI： 10.2169/internalmedicine.7124-21

PubMed

researchmap

Exacerbation of pulmonary cryptococcosis associated with enhancement of Th2 response in the postpartum period. 査読国際誌

Shota Miyoshi, Naohiro Oda, Yuka Gion, Takahiro Taki, Reo Mitani, Ichiro Takata, Akihiko Taniguchi, Yasuharu Sato, Nobuaki Miyahara

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 27 ( 8 ) 1248 - 1250 2021年8月

担当区分：最終著者記述言語：英語掲載種別：研究論文（学術雑誌）

Cryptococcosis is an invasive mycosis that has become increasingly prevalent in immunocompromised patients. Pregnant women are also one of the risk populations for cryptococcosis. Reversal of Th2 to Th1 response following resolution of immunosuppression during the postpartum period can lead to overt clinical manifestations of a previously silent infection, resembling an immune reconstitution inflammatory syndrome. Here, we report a case of a 30-year-old woman who had an exacerbation of pulmonary cryptococcosis in the postpartum period mimicking an immune reconstitution inflammatory syndrome. In the present case, chest computed tomography showed multiple small nodules on the day of the delivery; however, pulmonary cryptococcosis, which was subclinical during pregnancy, rapidly worsened to mass-like consolidation at one month after the delivery. Pathohistological examination of the lung specimen showed lung parenchyma infiltration with histiocytes and numerous lymphocytes without granulomatous formations, and a small number of yeast-like organisms consistent with Cryptococcus without capillary involvement. Immunohistochemical staining showed predominance of CD3+ cells and CD4+ cells over CD8+ cells. In addition, GATA3+ cells dominated over T-bet + cells. These data suggested exacerbation of pulmonary cryptococcosis associated with enhancement of Th2 response in the postpartum period.

DOI： 10.1016/j.jiac.2021.03.025

PubMed

researchmap

経食道的気管支鏡下穿刺吸引生検法(EUS-B-FNA)後に縦隔血腫を来した1例査読

南大輔, 柴田祐作, 中村香葉, 村上悦子, 宮原信明, 岸野大蔵, 瀧川奈義夫, 吉川真生, 田尾裕之, 水谷尚雄, 堀田真智子, 山岡正和, 廣岡空良, 石崎秀美

姫路赤十字病院誌 45 15 - 18 2021年7月

Loss of IL-33 enhances elastase-induced and cigarette smoke extract-induced emphysema in mice. 査読国際誌

Daisuke Morichika, Akihiko Taniguchi, Naohiro Oda, Utako Fujii, Satoru Senoo, Junko Itano, Arihiko Kanehiro, Yoshiaki Kitaguchi, Masanori Yasuo, Masayuki Hanaoka, Takashi Satoh, Shizuo Akira, Katsuyuki Kiura, Yoshinobu Maeda, Nobuaki Miyahara

Respiratory research 22 ( 1 ) 150 - 150 2021年5月

担当区分：最終著者,　責任著者記述言語：英語掲載種別：研究論文（学術雑誌）

BACKGROUND: IL-33, which is known to induce type 2 immune responses via group 2 innate lymphoid cells, has been reported to contribute to neutrophilic airway inflammation in chronic obstructive pulmonary disease. However, its role in the pathogenesis of emphysema remains unclear. METHODS: We determined the role of interleukin (IL)-33 in the development of emphysema using porcine pancreas elastase (PPE) and cigarette smoke extract (CSE) in mice. First, IL-33-/- mice and wild-type (WT) mice were given PPE intratracheally. The numbers of inflammatory cells, and the levels of cytokines and chemokines in the bronchoalveolar lavage (BAL) fluid and lung homogenates, were analyzed; quantitative morphometry of lung sections was also performed. Second, mice received CSE by intratracheal instillation. Quantitative morphometry of lung sections was then performed again. RESULTS: Intratracheal instillation of PPE induced emphysematous changes and increased IL-33 levels in the lungs. Compared to WT mice, IL-33-/- mice showed significantly greater PPE-induced emphysematous changes. No differences were observed between IL-33-/- and WT mice in the numbers of macrophages or neutrophils in BAL fluid. The levels of hepatocyte growth factor were lower in the BAL fluid of PPE-treated IL-33-/- mice than WT mice. IL-33-/- mice also showed significantly greater emphysematous changes in the lungs, compared to WT mice, following intratracheal instillation of CSE. CONCLUSION: These observations suggest that loss of IL-33 promotes the development of emphysema and may be potentially harmful to patients with COPD.

DOI： 10.1186/s12931-021-01705-z

PubMed

researchmap

Interstitial Pneumonia Secondary to Hermansky-Pudlak Syndrome Type 4 Treated with Different Antifibrotic Agents. 査読国際誌

Junko Itano, Yasushi Tanimoto, Goro Kimura, Noboru Hamada, Hisaaki Tanaka, Shinsuke Ninomiya, Kenjiro Kosaki, Nobuaki Miyahara, Yoshinobu Maeda, Katsuyuki Kiura

Internal medicine (Tokyo, Japan) 60 ( 5 ) 783 - 788 2021年3月

記述言語：英語掲載種別：研究論文（学術雑誌）

Hermansky-Pudlak syndrome (HPS) is an autosomal recessive hereditary disease that may be complicated by progressive and potentially fatal interstitial pneumonia. We herein report a 64-year-old woman with interstitial pneumonia associated with HPS type 4 whom we treated with nintedanib after pirfenidone proved ineffective. To our knowledge, there have been no previous reports of nintedanib being used to treat a patient with HPS type 4. There is a need for clinical trials of antifibrotic agents, including nintedanib, pirfenidone, and new therapeutic agents with different mechanisms of action in these patients.

DOI： 10.2169/internalmedicine.5493-20

PubMed

researchmap

　前のページ - 次のページ　

<宮原 信明>

論文 - 宮原 信明

<宮原　信明>

論文 - 宮原　信明